Category Archives: Sachdeva News

FAMU CoPPS, IPH Professor Receives Medical Marijuana Clinical Outcomes Research Grant
25 Jun

FAMU CoPPS, IPH Professor Receives Medical Marijuana Clinical Outcomes Research Grant

Florida A&M College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health (CoPPS, IPH) professor, Mandip Sachdeva, Ph.D., has been awarded a $67,500 research project grant from the Consortium for Medical Marijuana Clinical Outcomes Research (Consortium) for his proposal titled, “Evaluation of Minor Cannabinoids  loaded Exosomes in Chronic Diabetic Neuropathy.”

The Consortium received 24 proposals, and eleven awards were granted. Investigators submitted proposals from different consortium member institutions. In addition, an ad-hoc of out-of-state faculty reviewers reviewed proposals with demonstrated expertise in the respective research area. Funding recommendations were made after thoughtful and careful consideration of the merit of each proposal and its contribution to the consortium research mission.

The consortium research mission per statute is to contribute to understanding the effects of medical marijuana use and to promote informed decisions regarding policy and clinical practice related to the treatment of debilitating medical conditions with marijuana.

Funding for Sachdeva’s project will be approved for the period starting July 1, 2021, and ending on June 30, 2022.

 

New Colorectal Cancer Screening Recommendations Heralded
21 May

New Colorectal Cancer Screening Recommendations Heralded

New Colorectal Cancer Screening Recommendations Heralded

TALLAHASSEE, Florida ˗ Florida Agricultural and Mechanical University’s (FAMU) Center for Health Disparities Research heralds the new colorectal cancer screening recommendations by the United States Preventive Services Task Force (USPSTF).

The USPSTF’s 2021 final recommendation statement on colorectal cancer (CRC) screening, published May 18, 2021, in the Journal of the American Medical Association, updates the panel’s 2016 CRC screening recommendations. The USPSTF is an independent body of national experts in disease prevention and evidence-based medicine.

Colorectal cancer is the third leading cause of cancer death in the United States for both men and women, with an estimated total of 52,980 deaths in 2021. However, CRC is also one of the most treatable forms of cancer—if detected early by regular screening. “The importance of the USPSTF’s new CRC screening recommendations, most notably, the recommendation for all average-risk persons to begin screening at age 45, cannot be understated,” said Dr. John Luque, Associate Professor in FAMU’s Center for Health Disparities Research. Beginning screening at age 45 is also recommended by the American Cancer Society and American Society of Colon and Rectal Surgeons.

Regular screening starting at age 45 is important for all persons regardless of race/ethnicity. However, African Americans receive CRC screening at lower rates than White adults and this partially explains why African Americans experience the highest rates of CRC incidence and mortality compared to all other racial/ethnic groups.

In partnership with Big Bend Community Health Centers (Bond Community Health Center and Neighborhood Medical Center) and CRC screening experts from MUSC Hollings Cancer Center (Charleston, SC) and Moffitt Cancer Center (Tampa, FL), Dr. Luque is leading a multi-year CRC screening study funded by the National Institute on Minority Health and Health Disparities (NIMHD) of the U.S. National Institutes of Health (NIH). The study will assess whether a community health advisor educational intervention increases CRC screening among African Americans 45-64 years of age, compared to the usual approach to encourage screening.

Specifically, Luque explained, “we are investigating whether CRC screening with the stool-based test can be increased in this population for those who are not up-to-date, especially in light of the drop in preventive screenings due to the Covid-19 pandemic.” Luque added that stool-based tests such as the fecal immunochemical test (FIT) are effective, less costly, non-invasive, and often easier to access than colonoscopy. Colonoscopy is the gold standard for CRC screening in the United States, but it may be difficult for people who are uninsured or underinsured to access and some persons may be reluctant to receive colonoscopy due to fear or other factors, said Luque. “It is important to note that the new USPSTF recommendations emphasize the importance of providing patients with various approaches to screening to improve compliance with some form of screening. “As public health and medical professionals, we often say, ‘the best CRC screening is the one that gets done.’” Luque noted.

The FAMU Center for Health Disparities Research was established in 1985 through NIH funding mandated by Congress to support minority-serving institutions. Dr. Luque’s CRC screening study, the Test Up Now Education Program (TUNE-UP) is currently recruiting African Americans between 45 and 64 years of age who are out-of-date with their CRC screening. To participate, individuals must be patients of one of the two area community health centers, Bond Community Health Center or Neighborhood Medical Center. The collaborating health centers support the TUNE-UP project by processing participants’ FIT tests. Interested persons can learn if they qualify to participate in TUNE-UP by contacting the project coordinator, Matthew Vargas, at 850-766-3976 or matthew.vargas@famu.edu.

https://jamanetwork.com/journals/jamasurgery/fullarticle/2780038

https://www.uspreventiveservicestaskforce.org/uspstf/announcements/final-recommendation-statement-screening-colorectal-cancer-0

https://pharmacy.famu.edu/rcmi/ 

Sachdeva Named Senior Fellow of the National Academy of Inventors
21 May

Sachdeva Named Senior Fellow of the National Academy of Inventors

Florida A&M University College of Pharmacy & Pharmaceutical Sciences, Institute of Public Health (FAMU CoPPS, IPH), Pharmaceutical Sciences Professor, Mandip Sachdeva, Ph.D., was recently accepted as a Senior Fellow by the National Academy of Inventors (NAI) due to the impressive body of research and inventorship work he has created throughout his illustrious career. Dr. Sachdeva is the first member to receive this accomplishment at the University.

 

The NAI, founded in 2010, is a member organization comprising U.S. and international universities and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. The organization was created to recognize and encourage inventors with patents issued from the U.S. Patent and Trademark Office (USPTO).

 

Senior Members are elected annually on Inventors Day (February 11). The NAI Senior Member Advisory Committee elected Dr. Sachdeva for his “success in patents, licensing, and commercialization” and producing “technologies that have brought or aspire to bring, real impact on the welfare of society. Senior Members are active faculty, scientists, and administrators at NAI Member Institutions. Senior Members also foster a spirit of innovation within their communities through enhancing an inventive atmosphere at their institutions while educating and mentoring the next generation of inventors. The NAI Senior Member Advisory Committee comprises NAI members and other professionals considered pioneers in their respective fields. This latest class of NAI Senior Members represents 36 research universities, government, and non-profit research institutes, and they are named inventors on over 617 issued U.S. patents.

 

Dr. Sachdeva has been named as an inventor or co-inventor on 24 invention files. The most recently issued patent he has is for the “Self-Emulsifying Formulation of Carp-1 Functional Mimetics”. Dr. Sachdeva has worked on a myriad of biochemical inventions. However, he is exceptionally skilled in cancer drug delivery methods and techniques. Currently, Dr. Sachdeva has eight issued patents and seven more, which are still pending.

 

“I am very humbled by this honor from the National Academy of Inventors,” said Dr. Sachdeva. I intend to keep working towards my goal of filing more inventions with the hope of commercializing some of them. This honor and recognition motivate me to keep working in my research with more passion.”

 

“The Pharmaceutical Sciences Division is very proud to have one of our own receive this high distinction,” said Associate Dean of Pharmaceutical Sciences, Dr. Selina Darling-Reed. “Dr. Sachdeva richly deserves this honor as he has always been a leader in the development of innovative research approaches. While serving at FAMU, he has made great strides in the field of pharmaceutics for over 25 years as a teacher, researcher, inventor, and mentor to many graduate students.”

 

 

Dr. Sachdeva will be officially inducted as a Senior Member at the NAI 10th Anniversary Annual Meeting on October 31- November 3, 2021, in Tampa, Florida.

 

FAMU Holds Breast Cancer Awareness Symposium
11 Dec

FAMU Holds Breast Cancer Awareness Symposium

By: Reporter Jennifer Meyers

Breast Cancer Awareness
TALLAHASSEE, FL (WTXL) – With the National Institutes of Health’s P-20 grant, Florida A&M University has been working diligently on cancer research, training, and minority outreach programs.

One of these outreach programs included a symposium on Wednesday. FAMU invited many cancer researchers and survivors to discuss their research and share experiences.

Some of the topics discussed involved breast cancer in the minority population.
“If you look at the minority populations, there’s more incidents of triple-negative breast cancer, or breast cancer in the minority population,” said Dr. Mandip Sachdeva, a professor and Section Leader of Pharmaceutics Activity at Florida A&M. “There’s a lot of concern by NIH and NCI to look into this.”

This is the second symposium FAMU has held using the P-20 grant funding. The ultimate goal is to reduce the breast cancer rates among the minority population.

FAMU College of Pharmacy Prints 3D Cornea Using Human Cells
05 Nov

FAMU College of Pharmacy Prints 3D Cornea Using Human Cells

Florida A&M University (FAMU) College of Pharmacy & Pharmaceutical Sciences (COPPS) researchers have, for the first time in the United States, created corneas using a high performance 3D printer.

Funded by the National Science Foundation, the project is geared toward 3D printing and additive processing and could lead to breakthroughs in helping patients with eye problems and reduce the need to conduct testing on animals.  

FAMU Pharmacy professor Mandip Sachdeva, Ph.D., who leads the three-person team, said this process of manufacturing corneas using high throughput 3D printing technology, which could print a number of corneas in a matter of minutes, should become routine.  

The group, which includes, Shallu Kutlehria, a doctoral student from India, and Paul Dinh, a biology major from Tallahassee, spent the past year and a half creating an entire 3D model of a blinking eyeball. The corneas are printed in 3D by a bio-printer and made from materials including human cells.

Research assistant Dinh, 20, became interested in the field while in high school. He said this project requires pushing the envelope on cutting-edge technology. 

“Regular 3D printers, normally extrude some sort of hot plastic that eventually takes the shape of whatever you want,” Dinh said. “With a bio-printer, instead of extruding a hot plastic, we can extrude materials that are similar or present in the human body.” 

A United Kingdom scientist created the cornea technology, but the FAMU laboratory is working to make it more efficient by creating a mold to print multiple corneas. The diameter and dimensions of an average cornea are entered into the printer, taking nearly 10 minutes to produce six corneas. 

“From there, we can set up an assembly of 3D-printed corneas in a diffusion cell system and then test a lot of formulations or products at the same time and evaluate the data thus minimizing animal testing,” Sachdeva said.  

The corneas will then be entered into an artificial blinking eye, tear fluid and all, which was also printed in 3D, allowing the products to be tested in a simulated atmosphere. 

While there is still a lot of innovation to be done in the field, they are only weeks away from inserting the cornea into the eye model. 

“The ultimate goal is to file some patents as we move forward,” said Sachdeva. 

The visually impaired will benefit from this technology, said Dinh. 

“I can go and travel and see all these beautiful things and then there’s people out there that can’t really see at all,” he said. “It really made me appreciate the work that I was doing and that it had meaning to it and maybe my work can help someone in the future.” 

This article originally appeared on FAMUFOWARD on June 11th, 2019